Market Place
Sourcing Support
Aadi Bioscience Reports Q3 2024 Results & Corporate Update
06 Nov 2024 //
PR NEWSWIRE
Aadi Bioscience to Lay Off 80% of R&D Staff
21 Aug 2024 //
BIOSPACE
Aadi Bioscience Announces Q2 2024 Results And Provides Update
07 Aug 2024 //
PR NEWSWIRE
Aadi Nab-Sirolimus Tumor Data: Preferential Uptake At Asco 2024
23 May 2024 //
PR NEWSWIRE
Aadi: nab-Sirolimus Combo Data At AACR
09 Apr 2024 //
PR NEWSWIRE
Aadi Bioscience to Report Fourth Quarter and Full-Year 2023 Results
06 Mar 2024 //
PR NEWSWIRE
Aadi Bioscience to Present Multiple Posters at AACR Annual Meeting 2024
05 Mar 2024 //
PR NEWSWIRE
Aadi Announces Publication of Long-Term Efficacy Data Further Supporting FYARRO
01 Mar 2024 //
PR NEWSWIRE
Aadi Bioscience to Present at the TD Cowen 44th Annual Healthcare Conference
26 Feb 2024 //
PR NEWSWIRE
Aadi Bio Announces Poster Presentations at the 2024 ASCO GI Cancers Symposium
19 Jan 2024 //
PR NEWSWIRE
Aadi Reports Results from Trial of nab-Sirolimus Showing Anti-Tumor Activity
14 Dec 2023 //
PR NEWSWIRE
Aadi Bioscience Reports Financial Results for the Third Quarter 2023
08 Nov 2023 //
PR NEWSWIRE
Aadi Bioscience to Participate in Jefferies London Healthcare Conference
06 Nov 2023 //
PR NEWSWIRE
Aadi Bioscience to Report Third Quarter 2023 Results and Operational Update
01 Nov 2023 //
PR NEWSWIRE
Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC
12 Oct 2023 //
PR NEWSWIRE
Aadi Bioscience Announces Poster Presentations at NANETS 2023 Symposium
05 Oct 2023 //
PR NEWSWIRE
Aadi Bioscience Grants New CEO Dave Lennon
03 Oct 2023 //
PR NEWSWIRE
Aadi Appoints Dave Lennon, Ph.D. as President and Chief Executive Officer
02 Oct 2023 //
PR NEWSWIRE
Aadi Bioscience Announces Financial Results for the Second Quarter 2023
09 Aug 2023 //
PR NEWSWIRE
Aadi Bioscience to Report Second Quarter 2023 Results and Operational Update
02 Aug 2023 //
PR NEWSWIRE
Aadi Bioscience Announces Presentations at ASCO Annual Meeting
25 May 2023 //
PR NEWSWIRE
Aadi Bioscience to Participate in Upcoming Investor Events
23 May 2023 //
PR NEWSWIRE
Aadi Bioscience Announces FYR and Operational Update for the 1Q 2023
10 May 2023 //
PR NEWSWIRE
Aadi Bioscience to Report 1Q 2023 Results and Operational Update
03 May 2023 //
BUSINESSWIRE
Aadi Bioscience to Present Multiple Posters on nab-Sirolimus at the 2023 AACR
14 Apr 2023 //
PR NEWSWIRE
Aadi to Present Multiple at the AACR Annual Meeting 2023
06 Apr 2023 //
PR NEWSWIRE
Aadi Bioscience Announces Financial Results for the Fourth Quarter 2022
28 Mar 2023 //
PR NEWSWIRE
Aadi Bioscience Appoints Mohammad Hirmand, M.D. to Board of Directors
27 Mar 2023 //
PR NEWSWIRE
Aadi to Report Fourth Quarter and Full-Year 2022 Results and Corporate Update
15 Mar 2023 //
PR NEWSWIRE
Aadi Bioscience Announces Leadership Transition
03 Mar 2023 //
PR NEWSWIRE
Aadi Presents PRECISION 1 Trial in Progress Poster & AMPECT Trial Final Analysis
17 Nov 2022 //
PRNEWSWIRE
Aadi Bioscience Announces Planned Leadership Transition
08 Nov 2022 //
PRNEWSWIRE
Aadi Announces Improved Anti-Tumor Activity of KRAS Inhibitors
27 Oct 2022 //
PRNEWSWIRE
Mirati & Aadi Partner to Evaluate the Combination of Adagrasib & Nab-sirolimus
12 Oct 2022 //
PRNEWSWIRE
Aadi Bioscience Announces $72.5 Million Private Placement Equity Financing
22 Sep 2022 //
PRNEWSWIRE
Aadi Announces Participation in Upcoming September Investor Conferences
01 Sep 2022 //
PRNEWSWIRE
Aadi Bioscience to Report Second Quarter 2022 Results and Corporate Update
28 Jul 2022 //
PRNEWSWIRE
Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes
23 Jun 2022 //
PRESS RELEASE
Aadi Bioscience to Join Russell 2000 and Russell 3000 Indexes
23 Jun 2022 //
GLOBENEWSWIRE
Aadi Bioscience to Present at the Jefferies Global Healthcare Conference
01 Jun 2022 //
GLOBENEWSWIRE
Aadi Bioscience Appoints M. Graham SVP Investor Relations
31 May 2022 //
GLOBENEWSWIRE
Aadi Bioscience Announces Exploratory Biomarker Data from AMPECT Trial and EAP
26 May 2022 //
GLOBENEWSWIRE
Aadi Bioscience to Present at the H.C. Wainwright Global Investment Conference
18 May 2022 //
GLOBENEWSWIRE
Aadi Bioscience Reports First Quarter 2022 Financial Results
12 May 2022 //
GLOBENEWSWIRE
Aadi Bioscience Reports First Quarter 2022 Financial Results
12 May 2022 //
GLOBENEWSWIRE
Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders
09 May 2022 //
GLOBENEWSWIRE
Aadi Bioscience Announces Unique Permanent J-code Issued for FYARRO
04 May 2022 //
GLOBENEWSWIRE
Aadi Bioscience to Announce First Quarter 2022 Financial Results on May 12, 2022
28 Apr 2022 //
GLOBENEWSWIRE
Aadi Bioscience to Participate at the Jefferies “Biotech on the Bay Summit
18 Apr 2022 //
GLOBENEWSWIRE
Aadi Bioscience Presents Data on incidence of TSC1, TSC2 Alterations in Cancers
08 Apr 2022 //
GLOBENEWSWIRE
Aadi Bio Begins Dosing in Phase 2 Trial of nab-Sirolimus in Solid Tumors
31 Mar 2022 //
GLOBENEWSWIRE
Aadi Reports Q4 and FY 2021 Financial Results
17 Mar 2022 //
GLOBENEWSWIRE
Aadi Bio to Participate in Cowen`s 42nd Annual Health Care Conference
01 Mar 2022 //
GLOBENEWSWIRE
Aadi Bio Announces U.S. Commercial Launch and Availability of FYARRO
23 Feb 2022 //
GLOBENEWSWIRE
Aadi clinches first FDA nod for ultrarare sarcoma drug Fyarro
24 Nov 2021 //
YAHOOFINANCE
Aadi Bioscience Announces FDA Approval of its First Product FYARRO™
23 Nov 2021 //
GLOBENEWSWIRE
Aadi Bioscience Presents Two Abstracts on FYARRO (nab-Sirolimus)
15 Nov 2021 //
GLOBENEWSWIRE
Aadi Bioscience Presents Two Abstracts on FYARRO at (CTOS)
13 Nov 2021 //
GLOBENEWSWIRE
Gilead`s Immunomedics CMO exits to Aadi as it nears FDA decision
26 Oct 2021 //
FIERCEBIOTECH
